KRIBIOLISA Neutralizing Antibodies to Dupilumab (DUPIXENT) ELISA includes features like:
– Ready to use protocol with break-apart wells for ease of use
– Standardisation and High Reproducibility
– Lot to Lot Consistency
– Accuracy and Precision
Validated against seven points for a ?GOLD RING? Standard Quality ELISA – the benchmark sign for Krishgen Quality. KRIBIOLISA ELISA kit is used for assessing the specific biomarker in samples analytes which may be human serum, plasma, biological fluids and cell culture supernatant. The kit uses indirect sandwich assay with double antibodies / recombinant proteins – capture and detection to ensure a high degree of sensitivity and specificity in the estimation of the analyte. Extensive validation has been done on these kits. Please ask for our validation guide if not availableon our product page. Incase you wish us to customize the kit, connect with us at sales1@krishgen.com
Background: The KRIBIOLISA? ELISA kits are used for assessing the specific biomarker in samples analytes which may be serum and cell culture supernatant as validated with the kit. The kit employs a blocking ELISA technique which engages the blocking pathway to estimate the neutralizing antibodies. Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reactions in several atopic or allergic conditions, such as eczema, allergic reaction, and rhinosinusitis. Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. A neutralizing antibody (NAb) is an antibody that is responsible for defending cells from pathogens and are produced naturally by the body as part of its immune response. Their production is triggered by both infections and vaccinations against infections. In an immunogenetic context it will bind to a drug and neutralize its therapeutic effect. Intended Use: The KRIBIOLISA? Neutralizing Antibodies to Dupilumab (Dupixent) ELISA kit is used as an analytical tool for the qualitative detection of neutralizing antibodies against Dupilumab in serum or plasma. Principle: The method employs sandwich ELISA technique. The protein-protein interaction between HRP-Dupilumab and IL-4R can be blocked by Dupilumab. The neutralizing antibodies against Dupilumab bind to Dupilumab and thus a competitive inhibition is created. Samples and controls are pipetted in a blank microtitre plate and incubated with neutralizing antibody to Dupilumab (NAb) and Dupilumab. This complex of bound and unbound Dupilumab is then incubated with HRP conjugated Dupliumab protein. The unbound Dupilumab will bind to the Anti-IL-4R. The bound Nab-Dupilumab will not bind to the HRP conjugated Dupilumab. This complex solution of bound antibodies to Dupilumab and unbound Dupilumab is then pipetted into Anti-IL4R coated microplate. After washing, the substrate solution (TMB) is added to the microwells. Post incubation, color develops proportionate to the amount of bound Dupilumab. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!View more details about our Publication Reward